The FDA approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
The FDA Friday approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
The decision was based on data from the phase 2 ZUMA-5 trial (NCT03105336), in which the chimeric antigen receptor (CAR) T-cell treatment elicited a response in 91% of patients with relapsed or refractory follicular lymphoma (n = 81); 74% of patients had a continued remission at 18 months.
Among all patients with follicular lymphoma, the median duration of response was not reached at a median follow-up of 14.5 months.
In the safety analysis conducted in 146 patients, grade 3 or higher cytokine release syndrome and neurologic adverse effects were reported in 8% and 21% of patients, respectively.
In a statement late Friday, Kite, a Gilead company, said the approval marks the first CAR T-cell therapy approved for patients with indolent follicular lymphoma, follows FDA Breakthrough Therapy Designation and a priority review, as well as the third approved indication for a Kite cell therapy.
For these patients in the third line of therapy, the 5-year survival rate is only 20%, said Caron A. Jacobson, MD, MMSc, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute and Assistant Professor of Medicine, Harvard Medical School.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More